Skip to main content Accessibility help
×
Home
Hostname: page-component-6c8bd87754-g6grg Total loading time: 0.368 Render date: 2022-01-19T20:54:47.692Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

36 - Management of skin cancer other than melanoma

Published online by Cambridge University Press:  05 November 2015

Sankha Suvra Mitra
Affiliation:
Sussex University Hospitals NHS Trust, Brighton, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

Introduction

Non-melanoma skin cancer is the commonest cancer in the UK. It is usually caused by ultraviolet radiation from chronic sun exposure in a fair-skinned population. Basal cell carcinoma is the most frequent variety (74%), and presents as a superficial tumour that very rarely metastasises. Squamous cell carcinoma (23%) can spread to regional lymph nodes.

Surgical excision is the treatment of choice for the majority of tumours. Non-surgical treatment options include radiotherapy, curettage, imiquimod cream, photodynamic therapy and topical 5-FU therapy. Radiotherapy is an important treatment option for older patients and is preferred to surgery for large superficial tumours, multiple tumours, and in areas around the eye, nose and ear where the cosmetic results may be better and function can be preserved. The radiotherapy technique involves treatment with either superficial X-rays (SXR) or electron therapy. Cure rates are about 95% at 5 years.

The National Institute for Health and Clinical Excellence has published service guidance on the care of these patients (NICE, 2006).

Range of tumours

In the differential diagnosis, the tumour could be benign or malignant, and a malignant tumour could be either primary or secondary.

Premalignant conditions

Premalignant conditions include the following (Soutar and Robertson, 2001):

  1. • actinic keratosis;

  2. • Bowen's disease;

  3. • erythroplasia of Queyrat;

  4. • Paget's disease.

Benign tumours

Benign tumours include the following:

  1. • benign naevus;

  2. • sebaceous cyst;

  3. • epidermal cyst;

  4. • basal cell papilloma (seborrhoeic keratosis);

  5. • vascular angioma;

  6. • keratoacanthoma;

  7. • dermatofi broma .

Malignant tumours

Primary malignant tumours include:

  1. • basal cell carcinoma;

  2. • squamous cell carcinoma;

  3. • Merkel cell carcinoma;

  4. • malignant eccrine porocarcinoma;

  5. • amelanotic melanoma;

  6. • cutaneous T-cell lymphoma;

  7. • primary cutaneous B-cell lymphoma;

  8. • Kaposi's sarcoma;

  9. • angiosarcoma;

  10. • lymphangiosarcoma;

  11. • atypical fi broxanthoma.

Secondary malignant tumours can arise from any primary site, but occur most commonly from breast cancer, lung cancer, colon cancer and melanoma.

Incidence and epidemiology

There were about 100,000 cases of non-melanoma skin cancer in the UK in 2010. This comprises about 20% of all new cancers and there are about 500 deaths annually. More than 5% of the population over age 60 will develop a non-melanoma skin cancer (American Cancer Society, 2003).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Cancer Society. (2003). Cancer Facts and Figures. Atlanta: American Cancer Society.
Avril, M. F., Auperin, A., Margulis, A., et al. (1997). Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br. J. Cancer, 76, 100–106.CrossRefGoogle ScholarPubMed
Caccialanza, M., Piccinno, R., Moretti, D., et al. (2003). Radiotherapy of carcinomas of the skin overlying the cartilage of the nose: results in 405 lesions. Eur. J. Dermatol., 13, 462–465.Google ScholarPubMed
Coyle, C. (2005). The role of brachytherapy at miscellaneous sites: skin. In Radiotherapy in Practice: Brachytherapy, ed. Hoskin, P. and Coyle, C.. Oxford: Oxford University Press.Google Scholar
Dabski, K. and Helm, F. (1988). Topical chemotherapy. In Skin Cancer: Recognition and Management, ed. Schwartz, R. A.. New York: Springer-Verlag, pp. 378–389.Google Scholar
Diepgen, T. L. and Mahler, V. (2002). The epidemiology of skin cancer. Br. J. Dermatol., 146 (Suppl. 61), 1–6.CrossRefGoogle ScholarPubMed
Lebwohl, M., Dinehart, S., Whiting, D., et al. (2004). Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomised, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol., 50, 714–721.CrossRefGoogle Scholar
Lewis, K. G., Weinstock, M. A., Weaver, A. L., et al. (2006). Adjuvant local irradiation for Merkel cell carcinoma. Arch. Dermatol., 142, 693–700.CrossRefGoogle ScholarPubMed
Lovett, R. D., Perez, C. A., Shapiro, S. J., et al. (1990). External irradiation of epithelial skin cancer. Int. J. Radiat. Oncol. Biol. Phys., 19, 235–242.CrossRefGoogle ScholarPubMed
Malhotra, R., Huilgol, S. C., Huynh, N. T., et al. (2004). The Australian Mohs database, part II. Periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology, 111, 631–636.Google ScholarPubMed
National Comprehensive Cancer Network. (2005). Basal and squamous cell skin cancer guideline. In The Complete Library of NCCN Clinical Practice Guidelines in Oncology, version 1. Jenkintown, PA: National Comprehensive Cancer Network (CD-ROM).
NICE. (2006). Improving Outcomes for People with Skin Tumours Including Melanoma. London: National Institute for Health and Clinical Excellence.
NICE. (2010). Improving Outcomes for People with Skin Tumours Including Melanoma (update): The Management of Low-risk Basal Cell Carcinomas in the Community.London: National Institute for Health and Clinical Excellence.
Rubin, A. I., Chen, E. H. and Ratner, D. (2005). Basal-cell carcinoma. N. Engl. J. Med., 353, 2262–2269.CrossRefGoogle ScholarPubMed
Safai, B. (1997). Kaposi's sarcoma and acquired immunodeficiency syndrome. In AIDS: Epidemiology, Diagnosis, Treatment and Prevention, ed. DeVita, V. T., Hellman, S. and Rosenberg, S., 4th edn. Philadelphia, PA: Lippincott-Raven, pp. 295–358.Google Scholar
Sekulic, A., Migden, M. R., Oro, A. E., et al. (2012). Efficacy and safety of Vismodegib in advanced basal cell carcinoma. N. Engl. J. Med., 366, 2171–2179.CrossRefGoogle ScholarPubMed
Sekulic, A., Migden, M. R., Baset-Seguin, N., et al. (2013). Long term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18 month update of the pivotal ERIVANCE BCC study. J. Clin. Oncol., 31 (Suppl.; abstr. 9037).Google Scholar
Solan, M. J., Brady, L. W., Binnick, S. A., et al. (1997). Skin. In Principles and Practice of Radiation Oncology, ed. Perez, C. A. and Brady, L. W., 3rd edn. Philadelphia, PA: Lippincott-Raven, pp. 723–744.Google Scholar
Soutar, D. S. and Robertson, A. G. (2001). Skin cancer other than melanoma. In Oxford Textbook of Oncology, 2nd edn. Oxford: Oxford University Press, pp. 1235–1243.Google Scholar
Thomas, R. M. and Amonette, R. A. (1998). Mohs micrographic surgery. Am. Fam. Physician, 37, 135–142.Google Scholar
Tran, H., Chen, K. and Shumack, S. (2003). Summary of actinic keratosis studies with imiquimod 5% cream. Br. J. Dermatol., 149 (Suppl. 66), 37–39.CrossRefGoogle ScholarPubMed
UICC. (2009). TNM Classification of Malignant Tumours, ed. Sobin, L. H., Gospodarowicz, M. and Wittekind, Ch., 7th edn. Chichester: Wiley-Blackwell, pp. 165–168.

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×